Bayer AG (FRA:BAYN) Receives Consensus Rating of “Hold” from Analysts

Bayer AG (FRA:BAYN) has earned an average rating of “Hold” from the twenty-four ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, eleven have issued a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is €80.57 ($93.68).

Several equities analysts have recently weighed in on BAYN shares. Berenberg Bank set a €67.00 ($77.91) price target on shares of Bayer and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Deutsche Bank set a €70.00 ($81.40) price target on shares of Bayer and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. DZ Bank reissued a “neutral” rating on shares of Bayer in a research note on Wednesday, July 31st. Credit Suisse Group set a €70.00 ($81.40) target price on shares of Bayer and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Finally, JPMorgan Chase & Co. set a €69.00 ($80.23) target price on shares of Bayer and gave the stock a “neutral” rating in a research note on Monday.

The company’s fifty day moving average price is €58.70. Bayer has a 52 week low of €91.58 ($106.49) and a 52 week high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

See Also: Buy Rating

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.